Cell-based Parkinson's disease therapy - Titan Pharmaceuticals

Drug Profile

Cell-based Parkinson's disease therapy - Titan Pharmaceuticals

Alternative Names: Spheramine; TC-15

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Titan Pharmaceuticals
  • Developer Bayer Schering Pharma; Titan Pharmaceuticals
  • Class Antiparkinsonians; Cell therapies; Gene therapies; Neuroprotectants
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 02 Jul 2008 Suspended - Phase-II for Parkinson's disease in USA (Intrastriatal)
  • 30 Apr 2008 Four-year, follow-up efficacy and safety data from a clinical trial in patients with moderate-to-advanced Parkinson's disease released by Titan Pharmaceuticals
  • 19 Apr 2008 Pharmacodynamics data from a primate model of Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top